Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Recent studies indicate the benefit of treatment with osimertinib over that with conventional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for untreated EGFR-mutated non-small cell lung cancer (NSCLC). | Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies a retrospective study